文献速递眼底病与葡萄膜炎小儿眼科与斜弱视

儿童遗传性视网膜疾病基因治疗的疗效、安全性与持久性:范围综述

Efficacy, Safety, and Durability of Gene Therapy for Inherited Retinal Diseases in the Pediatric Population: A Scoping Review.
PubMed 文献 · Am J Ophthalmol · 2026-07-31

RPE65相关疾病证据最多且疗效与持久性信号最一致;AIPL1和GUCY2D补充治疗在少数幼儿中显示功能获益;CEP290相关干预早期信号有限;RPGR、CNGB3、RS1和MERTK证据不足以支持儿童特异性疗效结论。严重眼部事件主要为操作相关,未发现可重复的儿童特异性毒性信号。

要点

  • 儿童IRD基因治疗获益取决于基因型、残余视网膜结构、治疗平台、剂量、手术策略和结局指标。
  • RPE65相关疾病拥有最大儿童证据基础,但不同试验簇间反应存在差异。
  • 主要证据缺口为长期儿童持久性数据及年龄分层报告不一致。

核心结论

  • 儿童IRD基因治疗的获益由基因型、残余视网膜结构、治疗平台、剂量、手术策略和结局指标共同决定。
  • 现有证据的主要缺口是长期儿童持久性数据不足以及年龄分层报告不一致。

研究设计与样本

  • 本范围综述遵循前瞻性注册方案,检索PubMed和Embase自2008年1月1日至2026年4月13日的记录。
  • 由2名评审独立筛选前瞻性干预研究,纳入分子确诊IRD且入组18岁以下参与者的基因靶向治疗,分歧由第三名评审裁决。
  • 重叠报告按试验簇分组并设主要锚定记录;至少3名儿童参与者且儿童数据可单独提取的记录归为Tier 1并纳入主合成,其他合格记录保留为Tier 2背景证据。

主要发现

  • RPE65相关疾病提供最大儿童证据基础和最一致的疗效与持久性信号,但不同试验簇间反应存在差异。
  • AIPL1基因补充治疗在4名非常年幼儿童中显示治疗眼显著功能增益并伴相对结构保留,随访至4年。
  • 高剂量GUCY2D基因补充治疗在混合年龄队列中使3名儿童视网膜敏感性改善。
  • CEP290靶向剪接调节和基因编辑显示早期功能信号,但sepofarsen剂量相关白内障和EDIT-101儿童参与者少限制了解读。

关键数值与推荐

  • Tier 1纳入标准为记录中至少含3名儿童参与者且儿童数据可单独提取。
  • AIPL1基因补充治疗在4名非常年幼儿童中显示治疗眼功能增益和相对结构保留,随访至4年。
  • 高剂量GUCY2D基因补充治疗在3名儿童中改善视网膜敏感性。
  • sepofarsen与剂量相关白内障相关;EDIT-101的儿童参与者极少。

临床怎么用

  • 临床决策应基于具体基因型、残余视网膜结构、治疗平台、剂量和手术策略综合评估儿童IRD基因治疗的潜在获益。
  • 对RPE65相关疾病可参考较一致的儿童疗效与持久性信号,但需注意试验簇间反应差异。
  • 对AIPL1和GUCY2D相关疾病,现有少量儿童数据提示功能获益可能,但需在合适条件下谨慎评估。
  • 对RPGR、CNGB3、RS1和MERTK相关疾病,目前缺乏支持儿童特异性疗效的稳健证据。
  • 关注操作相关严重眼部事件,并对儿童患者进行长期随访以监测持久性。

局限性

  • 正式年龄分层分析不常见,部分儿童与成人模式需综述作者提取。
  • 长期儿童持久性证据不足。
  • 年龄分层报告不一致。
  • 部分基因型(如CEP290、EDIT-101)儿童参与者少或存在剂量相关不良事件,限制解读。
  • RPGR、CNGB3、RS1和MERTK证据不足以得出儿童特异性疗效结论。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To map the published interventional gene-based therapies relevant to children with inherited retinal diseases (IRDs), with a focus on efficacy, safety, and durability, including pediatric-vs-adult patterns where available. METHODS: This scoping review followed a prospectively registered protocol specifying the search strategy, eligibility criteria, screening process, data-charting framework, and synthesis plan. PubMed and Embase were searched from January 1, 2008, to April 13, 2026. Retrieved records were independently screened by 2 reviewers to identify prospective interventional studies of gene-targeted therapies for molecularly confirmed IRDs enrolling participants younger than 18 years; unresolved disagreements were adjudicated by a third reviewer. Overlapping reports were grouped into trial clusters with a primary anchor record. Records with at least 3 pediatric participants and separately extractable pediatric data were classified as Tier 1 and included in the main synthesis; other eligible records were retained as Tier 2 contextual evidence. Where sufficient individual-level or subgroup-level data were available, review authors extracted descriptive pediatric-vs-adult patterns. RESULTS: Twenty-four records, grouped into 17 trial clusters across 8 genotypes, were included; 14 met Tier 1 criteria. RPE65-associated disease provided the largest pediatric evidence base and the most consistent efficacy and durability signals, although responses varied between trial clusters. AIPL1 gene supplementation showed substantial treated-eye functional gains with relative structural preservation at up to 4 years in 4 very young children, and high-dose GUCY2D gene supplementation improved retinal sensitivity in 3 children within a mixed-age cohort. CEP290-targeted splice modulation and gene editing showed early functional signals, but interpretation was limited by dose-related cataract with sepofarsen and few pediatric participants with EDIT-101. Evidence for RPGR, CNGB3, RS1, and MERTK did not support robust pediatric-specific efficacy conclusions. Serious ocular events were predominantly procedure-related, with no reproducible pediatric-specific toxicity signal. Formal age-stratified analyses were uncommon, and several pediatric-vs-adult patterns required review-author extraction. CONCLUSIONS: Pediatric benefit from IRD gene therapy depends on genotype, residual retinal structure, therapeutic platform, dose, surgical strategy, and outcome measure. The major evidence gaps are long-term pediatric durability and inconsistent age-stratified reporting. Future pediatric-inclusive trials should prespecify subgroup analyses, embed prospective long-term follow-up, use developmentally appropriate endpoints, and report individual-level data sufficient to support pediatric inference.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Amato A, Iarossi G, Stephenson KA, et al. Efficacy, Safety, and Durability of Gene Therapy for Inherited Retinal Diseases in the Pediatric Population: A Scoping Review. Am J Ophthalmol. 2026. PMID: 42537978. doi:10.1016/j.ajo.2026.07.039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。